G01N33/723

IMMUNOASSAY REAGENT AND IMMUNOASSAY METHOD

The problem to be solved by the present invention is to provide a reagent that can reduce deposition of fouling in the reaction cell, by using an existing reaction cell, without affecting the composition of the reagent, in an immunoassay method using a reagent containing latex particles; and to provide an immunoassay method using the reagent.

Provided is an immunoassay reagent including a latex particle, wherein the latex particle contains a halogen atom. Also provided is an immunoassay method including contacting a latex particle with a sample to be measured in a reaction cell, wherein the latex particle contains a halogen atom.

METHOD FOR MEASUREMENT OF HEMOGLOBIN
20220187258 · 2022-06-16 · ·

A reagent for use in the measurement of hemoglobins by liquid chromatography, the reagent comprising a nonionic surfactant selected from the group consisting of:

(i) polyoxyethylene (10) decyl ether; (ii) polyoxyethylene (6) 2-ethylhexyl ether; (iii) polyoxyethylene (9) isodecyl ether; (iv) polyoxyethylene (10) nonyl ether; (v) polyoxyethylene (16) isostearyl ether; (vi) polyoxyethylene (20) behenyl ether; and (vii) polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether.

METHODS OF BLOOD SAMPLE SUSPENSION

Disclosed herein are methods for rapid detection of suspension of a blood sample from a subject and methods for improving the processing time of a point of care blood analysis. Specifically, the disclosed methods provide a rapid detection of hemoglobin concentration, more specifically glycated hemoglobin A1c, and determination of sugar concentration in the blood sample from the subject. Further disclosed herein are methods for rapidly diagnosing diabetes in a subject.

DRIED REAGENT POLYSACCHARIDE SURFACE AREA STABILIZATION
20220163543 · 2022-05-26 · ·

Non-limiting embodiments of a modified solid reagent zone comprising at least hydrophilic polysaccharide and/or at least one hydrophilic non-polysaccharide polymer for use in the conductance of at least one diagnostic assay, as well as kits and methods of use and production related thereto.

GLYCATED HEMOGLOBIN MEASUREMENT KIT

A glycated hemoglobin measurement kit including a reagent container, a cleaning solution, and a container holder. The reagent container has a cylindrical shape opened at opposite sides and includes a barrier membrane that blocks an opening at one side and forms a reagent storage part for a reagent for glycated hemoglobin measurement. The cleaning solution container has a cylindrical shape opened at opposite sides and includes an auxiliary barrier membrane that blocks an opening at one side and forms a cleaning solution storage part for a cleaning solution that cleans a reaction solution in which the blood and the reagent are mixed and react with each other. The container holder includes an attachment/detachment part from which a measurement strip is detachable and a measurement hole through which one area of the measurement strip attached to the attachment/detachment part is exposed.

Calibrators and controls for the determination of percent glycated hemoglobin in a patient's liquid test sample
11327081 · 2022-05-10 · ·

Non-limiting embodiments of methodologies for preparing diagnostic assay(s) calibrator(s), calibration material(s), and/or control(s), as well as kits, devices, and method(s) of calibration related thereto.

SYSTEMS AND METHODS FOR ELECTROCHEMICAL POINT-OF-CARE DETECTION OF HEMOGLOBIN
20230305026 · 2023-09-28 ·

A method is disclosed comprising lysing the red blood cells of a whole blood sample, oxidizing the free hemoglobin in the lysed sample, and cleaving FVH from the hemoglobin A1C to form an electrochemical test solution. In one aspect, a first portion of the electrochemical test solution is reacted with fructosyl peptide oxidase and a reduced ruthenium mediator to form a first reaction product. A first electrical property of the first reaction product is measured, the measurement being indicative of hemoglobin A1C in the blood sample. In another aspect, a second portion of the electrochemical test solution is reacted with ferrocyanide to form a second reaction product. A second electrical property of the second reaction product is measured, the measurement being indicative of total hemoglobin in the blood sample. Hemoglobin A1C, total hemoglobin, and % HbA1C are determined based on the first and second electrical properties. Also provided are systems and components useful in performing the disclosed methods.

Method for measurement of hemoglobin
11768184 · 2023-09-26 · ·

A reagent for use in the measurement of hemoglobins by liquid chromatography, the reagent comprising a nonionic surfactant selected from the group consisting of: (i) polyoxyethylene (10) decyl ether; (ii) polyoxyethylene (6) 2-ethylhexyl ether; (iii) polyoxyethylene (9) isodecyl ether; (iv) polyoxyethylene (10) nonyl ether; (v) polyoxyethylene (16) isostearyl ether; (vi) polyoxyethylene (20) behenyl ether; and (vii) polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether.

Measurement method for glycated hemoglobin ratio

Disclosed is a measurement method for a glycated hemoglobin ratio. According to a measurement method for a glycated hemoglobin ratio of the present invention, reagents are easy and convenient to use because of their sequential leakage during the rotation of a cassette, are all discharged by the rotation with no remaining reagent, and are not mixed with each other. Therefore, measurement results are accurate, with fewer errors in the quantities of used reagents and sample blood.

METHOD FOR DETERMINING THE HAEMOGLOBIN CONTENT OF AN ERYTHROID CELL

The invention concerns a method for determining, by flow cytometry, the hemoglobin content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the hemoglobin content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.